This site is intended for U.S. Healthcare Professionals only.
SOTYKTU is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Limitations of Use: SOTYKTU is not recommended for use in combination with other potent immunosuppressants.
Request a Rep
Visit Patient Site
Co-Primary vs Placebo
Week 16 Safety Profile
SOTYKTU, SOTYKTU 360 SUPPORT, and SOTYKTU logo are trademarks of Bristol-Myers Squibb Company.
Otezla is a registered trademark of Amgen Inc.
© 2023 Bristol-Myers Squibb Company.